Oncimmune Hldngs PLC

Block Listing Six Monthly Return

RNS Number : 5398U
Oncimmune Holdings PLC
06 April 2021

6 April 2021



Oncimmune Holdings plc


("Oncimmune" or the "Company")


Block Listing Six Monthly Return



Oncimmune makes the following notification pursuant to Schedule Six of the AIM Rules for Companies regarding its existing block admission arrangements in respect of Oncimmune Holdings Plc 2016 Unapproved and EMI Share Option Plans (the "Share Option Plans").


Name of applicant:

Oncimmune Holdings plc


Name of scheme:

Oncimmune Holdings Plc 2016 Unapproved and EMI Share Option Plans


Period of return:

15 September 2020 to 15 March 2021


Balance of unallotted securities under scheme(s) from previous return:



Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):



Less: Number of securities issued/allotted under scheme(s) during period:



Equals: Balance under scheme(s) not yet issued/allotted at end of period:





For further information:


Oncimmune Holdings plc

Ron Kirschner, Company Secretary

[email protected]


Zeus Capital Limited (Nominated Adviser and Joint Broker)

Andrew Jones, Daniel Harris, Victoria Ayton

+44 (0)20 3829 5000


N+1 Singer (Joint Broker)

Aubrey Powell, Harry Gooden, Iqra Amin, James Fischer

+44 (0)20 7496 3000


WG Partners (Joint Broker)

David Wilson, Chris Lee

+44 (0)203 705 9321


Media enquiries:

FTI Consulting

Ben Atwell, Michael Trace, Alex Davis

[email protected]

+44 (0)20 3727 1000

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.